Claudia Cecilia Ortiz, NP

Claudia Ortiz practices at San Joaquin Valley Pulmonary Group in Bakersfield, California.

Claudia Ortiz's NPI, 1912570391, was assigned on July 22, 2021. Claudia Ortiz holds California license 95017808.

Claudia Ortiz's primary practice is San Joaquin Valley Pulmonary Group, at 3551 Q St, Bakersfield, CA 93301 in Kern County. The practice phone is (661) 327-3747.

Claudia Ortiz's primary practice is San Joaquin Valley Pulmonary Group in Bakersfield, California. The medical group on file is Hoffmann Hospice. Dmand AI also links Claudia Ortiz to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Claudia Ortiz practices. Vendor and product names are available with a free account.

Nurse practitioner is Claudia Ortiz's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Claudia Ortiz is licensed in California.

CMS data shows 771 Medicare services from Claudia Ortiz across 8 procedure codes in 2024, for 167 Medicare patients. Medicare paid $46,549 for them. Every service was in an office.

CMS counts 167 Medicare patients who saw Claudia Ortiz in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 80% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Claudia Ortiz's median patient age at 53, with 62% women.

In 2024, Claudia Ortiz wrote 3,000 Medicare Part D claims for 313 patients. 83% of them were for generic drugs. CMS names the drug for 2,385 of them, across 73 drugs with 11 or more claims each, at $184,126 in total drug cost.

Claudia Ortiz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Claudia Ortiz as offering telehealth.

CMS Open Payments shows 173 general payments to Claudia Ortiz from 28 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $706.